Sunset Syringe Gunslinger at O.K. Corral — Image: AI-generated for CardioAdvocate
This article is for medical education purposes only. It does not constitute medical advice. Peptides discussed in this article include both FDA-approved medications and unapproved substances. Always consult your healthcare provider before starting, stopping, or changing any medication or supplement regimen.
Walk into any serious gym in America right now and listen. Between the clang of plates and the hum of treadmills, you'll hear it: "Have you tried peptides?"
It's whispered at the squat rack. It's discussed openly in the locker room. It's offered — sometimes literally at the front counter — by trainers, coaches, and that one jacked dude who seems to know a guy who knows a guy. Peptides have become the new frontier of what we'll call "gym bro medicine" — a parallel healthcare system operating outside the guardrails of evidence-based practice, where anecdote replaces clinical trials and Instagram testimonials stand in for peer-reviewed data.
And this isn't just happening at the fringe. Healthcare professionals — physicians, nurse practitioners, PAs — are using these substances themselves and, in some cases, recommending them to patients through channels that would make a pharmacovigilance officer reach for the smelling salts.
The peptide market is vast, but the conversation right now centers on two very different categories that are being dangerously conflated:
1. GLP-1 Receptor Agonists — FDA-approved, rigorously studied medications (semaglutide, tirzepatide) that are being obtained through compounding pharmacies and telehealth mills by people who don't meet the clinical criteria for their use.
2. "Research Peptides" — substances like BPC-157, TB-500, CJC-1295, and ipamorelin that have little to no human clinical data, are not FDA-approved, and are being injected by gym-goers based on animal studies and Reddit threads.
Both categories share a common thread: they are being used by people who believe they are taking a shortcut to health. Both carry risks that are poorly understood, with potential off-target effects we are only beginning to appreciate. And both exist in a regulatory gray zone that is, at best, chaotic — and at worst, dangerous.
Let's talk about what these substances actually are, what the evidence says, what the evidence doesn't say, and why "gym bro medicine" might be the most dangerous trend in modern wellness culture.
Part I: GLP-1 Receptor Agonists — The Real Deal (When Used Right)
What Are They?
GLP-1 receptor agonists are a class of medications that mimic a natural hormone called glucagon-like peptide-1 (GLP-1). Your body produces GLP-1 after eating — it's one of the "incretin" hormones that tell your pancreas to release insulin, tell your liver to slow down glucose production, slow gastric emptying so you feel full longer, and act on brain circuits that regulate appetite and reward.
The pharmaceutical versions — semaglutide (marketed as Ozempic, Wegovy, and Rybelsus) and tirzepatide (marketed as Mounjaro and Zepbound) — are synthetic peptides engineered to last much longer than your natural GLP-1, which survives only about 2 minutes before being broken down by the enzyme DPP-4. Semaglutide has a half-life of approximately one week, which is why it's a once-weekly injection.
Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, giving it a broader metabolic footprint. Think of semaglutide as a single-key lock, and tirzepatide as a master key that opens two doors simultaneously.
What Are They FDA-Approved For?
This matters enormously — because the population studied in the randomized controlled trials (RCTs) defines who we know these drugs work for, and who they're safe for. Here's what the FDA has actually approved:
Semaglutide:
• Ozempic — Type 2 diabetes and cardiovascular risk reduction in adults with T2D and established ASCVD
• Wegovy — Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; also for CV risk reduction
• Rybelsus — Oral form for type 2 diabetes
Tirzepatide:
• Mounjaro — Type 2 diabetes
• Zepbound — Chronic weight management (BMI ≥30, or ≥27 with comorbidity); also for moderate-to-severe obstructive sleep apnea
Notice what all of these have in common: every single indication is for people with disease. Type 2 diabetes. Obesity. Established cardiovascular disease. Sleep apnea. The landmark trials — STEP, SELECT, SURMOUNT, SURPASS — enrolled participants with a mean BMI in the range of 36 to 39. The SELECT trial, which demonstrated cardiovascular benefit, required participants to have established atherosclerotic cardiovascular disease and a BMI ≥27 — these were sick people, not gym rats looking to shave off their last 10 pounds for beach season.
When a 175-pound, 12%-body-fat fitness enthusiast takes semaglutide because they heard it "leans you out," they are not benefiting from the evidence base that justified this drug's approval. They are conducting an n=1 experiment on themselves — with a powerful pharmaceutical agent that modulates insulin, appetite, gastric motility, reward circuitry, and potentially much more.
The Compounding Pharmacy Controversy
Here's where the story gets ugly. During the COVID-era supply chain disruptions, the FDA placed semaglutide on its Drug Shortage List. Under federal law (specifically, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act), compounding pharmacies are permitted to produce copies of drugs that are in shortage — a reasonable provision designed to ensure patient access during emergencies.
What happened next was entirely predictable: hundreds of compounding pharmacies began producing "semaglutide" at a fraction of the cost of Ozempic or Wegovy. Telehealth companies sprang up overnight, connecting patients with prescribers who would authorize compounded versions after a brief online questionnaire. The barrier to entry dropped from "see your endocrinologist" to "fill out a web form."
Then, in February 2025, the FDA declared the semaglutide shortage officially over. The legal basis for compounding copies evaporated. The FDA gave compounders a wind-down period — enforcement discretion through April 22 for 503A pharmacies and May 22 for 503B outsourcing facilities.
But many compounders did not stop.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, launched what can only be described as a legal blitzkrieg. As of mid-2026, the company has filed over 132 complaints across 40 states, targeting compounding pharmacies and telehealth companies still producing or distributing unapproved semaglutide products. Courts have issued 44 permanent injunctions against defendants. A Texas federal court ruling in April 2025 rejected a preliminary injunction sought by compounders, reinforcing that it is illegal under U.S. compounding laws to make or sell knockoff semaglutide drugs outside the narrow shortage exception.
Novo Nordisk also sued Hims & Hers Health over a compounded semaglutide pill, asserting patent protection that extends until December 2031.
What's Actually in the Compounded Version?
This is where the biochemistry matters. Not all "semaglutide" is created equal.
The FDA-approved products (Ozempic, Wegovy) contain semaglutide base — the specific molecular entity that was tested in all of those rigorous clinical trials. Some compounding pharmacies, however, use salt forms — semaglutide sodium or semaglutide acetate. The FDA has been unambiguous about this distinction: these salt forms are not the same active ingredient as the branded products, and they have not been shown to be safe or effective.
This isn't pharmaceutical hairsplitting. A salt form can alter:
• Bioavailability — how much active drug actually reaches your bloodstream
• Stability — how the drug behaves in solution over time
• Pharmacokinetics — how quickly it's absorbed, distributed, and eliminated
• Immunogenicity — whether it triggers unwanted immune responses
Beyond the active ingredient, excipients vary between compounders. Two vials from two different pharmacies may contain entirely different formulations. There is no standardized quality control. There are no clinical trials testing these specific preparations. As one endocrinologist put it: "None of them have been tested in clinical trials for safety or efficacy."
The consequences are not theoretical. The FDA has received over 520 adverse event reports for compounded semaglutide and more than 480 for compounded tirzepatide, some requiring hospitalization. These included hospitalizations involving unidentified impurities. In August and September 2026, multiple compounding pharmacies in Texas issued recalls for injectable products with elevated endotoxin levels — with the FDA receiving reports of nausea, vomiting, tachycardia, and injection-site reactions from at least 30 patients. Both facilities had sourced their raw ingredients from the same manufacturer and were using supplement-grade raw materials — not pharmaceutical-grade — for injectable products.
Read that again: supplement-grade ingredients being used to make injectable drugs. This is the equivalent of building a bridge with lumber rated for a garden shed.
GLP-1 Agonists in Healthy, Lean People: What We Don't Know Could Hurt You
The clinical trials for semaglutide and tirzepatide enrolled people with a mean BMI of 36–39. The lowest entry threshold for the weight-loss trials was a BMI of 27 — and even then, the patient needed at least one weight-related comorbidity.
Now consider the typical gym-goer using compounded semaglutide: a 30-something with a BMI of 24, no diabetes, no cardiovascular disease, no sleep apnea. They want to drop from 15% body fat to 10%. There is zero clinical trial data on what these drugs do to that person.
What we do know raises legitimate concerns:
Muscle Loss: In the clinical trials, approximately 25–39% of weight lost was lean body mass, not fat. The concern here has a name: sarcopenia — the loss of skeletal muscle mass and function. For an obese person losing 40 pounds, losing some muscle along with the fat is a reasonable trade-off — the metabolic benefits of the fat loss vastly outweigh the muscle cost. But for a lean, active person who doesn't have much fat to lose? Losing a quarter of your weight loss from muscle is a completely different equation. And we have no data on whether resistance training fully mitigates this in already-lean populations.
Gallbladder Disease: A meta-analysis found that semaglutide increased gallbladder-related disorders by more than 2.6 times, primarily gallstones (cholelithiasis). Rapid weight loss is a well-known risk factor for gallstone formation — and a lean person losing weight quickly may be at even higher relative risk, since their baseline gallbladder function hasn't been stressed by years of obesity-related metabolic changes.
GI Effects: Nausea, vomiting, diarrhea, and constipation are the most common adverse effects. In a pooled analysis of the STEP 1–3 trials, nausea was reported by 43.9% of semaglutide users versus 16.1% on placebo, and vomiting by 24.5% versus 6.3%. Gastroparesis — delayed gastric emptying — has been reported in case series, though it remains rare. For someone using these drugs to look better at the beach, these are not trivial trade-offs.
The Cancer Question: Thyroid, Oncogenes, and the Unknown
Every GLP-1 receptor agonist carries a boxed warning — the FDA's most serious warning category — about the risk of medullary thyroid carcinoma (MTC). This warning stems from rodent studies in which semaglutide and other GLP-1 agonists caused thyroid C-cell tumors in rats and mice at clinically relevant exposures.
The human picture is more nuanced. A large real-world cohort study found that long-term GLP-1RA use was not associated with increased risk of thyroid cancer in adults with type 2 diabetes. A 2024 systematic review similarly found no conclusive evidence linking GLP-1 agonists to human thyroid cancer. However, a French case-control study did report a relative risk of 1.78 for thyroid cancer (all subtypes) in GLP-1 users, though the study had significant limitations including short follow-up and potential detection bias.
The absolute contraindication remains for patients with MEN2 syndrome (Multiple Endocrine Neoplasia type 2) — an inherited condition caused by mutations in the RET proto-oncogene that dramatically increases medullary thyroid cancer risk. GLP-1 agonists are strictly contraindicated in these patients and in anyone with a personal or family history of MTC.
But here's the question that should give every lean, healthy gym-goer pause: the cancer data comes from studies in obese and diabetic populations. Obesity itself is a well-established risk factor for multiple cancers. When an obese person loses weight with a GLP-1 agonist, any drug-related cancer risk may be offset by the cancer-protective effect of the weight loss itself. That calculus does not apply to a normal-weight person. A lean gym-goer gets the drug exposure without the protective counterbalance of meaningful fat loss.
Could GLP-1 receptor activation in normal-weight individuals carry oncogenic risk that is masked in obese populations by the benefits of weight loss? We don't know. We can't know — because no one has studied it. And absence of evidence is not evidence of absence.
The Pleasure Problem: GLP-1 Agonists and Your Reward Circuits
One of the most fascinating — and potentially most concerning — aspects of GLP-1 receptor agonists is their effect on the brain's mesolimbic dopamine system: the neural circuitry that governs reward, motivation, and pleasure.
Preclinical studies have consistently shown that GLP-1 agonists dampen dopamine signaling in the nucleus accumbens — the brain's "reward center." In animal models, semaglutide decreased alcohol-induced dopamine release, and similar effects have been demonstrated with cocaine, nicotine, and amphetamines. A 2025 meta-analysis in eClinicalMedicine reported that GLP-1 RAs, particularly semaglutide and liraglutide, significantly reduced alcohol consumption as measured by AUDIT scores. Observational data from Stanford suggest that people with opioid or alcohol use disorder who took GLP-1s had a 40% lower rate of opioid overdose.
For people struggling with addiction, this is potentially life-changing. Clinical trials are now underway.
But there's a shadow side to dampening the reward system. If you blunt the dopamine response to food, alcohol, and drugs — what happens to everything else that brings pleasure?
Case reports have described patients on GLP-1 agonists losing interest not just in food, but in sex, hobbies, social gatherings, exercise, and everyday enjoyment. A 2025 commentary noted that these reports suggest anhedonia may be dose-dependent — related to continuous, tonic receptor occupancy rather than being an inherent property of the drug class. A Turkish clinical trial is now specifically studying anhedonia and emotional eating in GLP-1 users.
For an obese patient whose relationship with food has been compulsive and destructive, reduced food preoccupation can be liberating. But for a healthy person who enjoys cooking, savoring a meal with friends, or the post-workout endorphin rush? Blunting the brain's reward circuitry is not a targeted intervention — it's a systemic dampening of one of the core neurological systems that makes life worth living.
Imagine an avid gym-goer — someone who trains because they love it, because the endorphin rush keeps them coming back — who starts a GLP-1 agonist to "lean out." What if the drug reduces their motivation to train? What if the dopamine reward from exercise becomes muted? What if the social pleasures that accompany gym culture — the camaraderie, the post-workout meal, the simple satisfaction of progress — become flat and uninteresting? The irony would be crushing: a drug taken to optimize the body that ends up undermining the very behaviors that were keeping the body healthy in the first place.
This isn't hypothetical. Clinicians are hearing it from patients: "I wasn't myself anymore. I just wasn't interested in things." It's a pattern that's emerging in practice — not yet captured in large datasets, but real enough that patients are discontinuing treatment over it.
What About Depression and Suicidality?
In 2023, Iceland's medicines agency flagged reports of suicidal thoughts and self-harm among GLP-1 RA users, triggering formal investigations by both the European Medicines Agency and the FDA. Both agencies concluded there was no evidence of a causal link between GLP-1 agonists and suicidality, though both stated they would continue monitoring.
A large Swedish registry study of 95,490 patients with depression or anxiety actually found the opposite: semaglutide was associated with a lower risk of worsening depression (adjusted hazard ratio 0.56) and anxiety (aHR 0.62), published in The Lancet Psychiatry in 2026. However, a JAMA Network Open case-control study from August 2024 found higher odds of suicidal ideation specifically in patients already on antidepressants — suggesting the risk may concentrate in a vulnerable subgroup.
Here's the problem with all of this data: people with pre-existing mental illness were excluded from the GLP-1 clinical trials. And every reassuring observational study comes from obese and diabetic populations — people whose depression and anxiety often improve with weight loss itself. That improvement could easily mask a drug-related psychological effect.
Now apply that to a lean, mentally healthy gym-goer who doesn't need to lose weight. There's no mood boost from fat loss to offset any neuropsychiatric effects of chronic dopamine suppression. We simply don't know what sustained GLP-1 receptor activation does to the psychology of someone who was fine before they started.
Part II: The Peptide Bazaar — What's Actually Being Sold at the Gym Counter
If GLP-1 agonists represent the pharmaceutical end of the spectrum — rigorously tested drugs being used off-label — the world of "research peptides" is the opposite extreme. These are substances with little to no human clinical data, sold in vials with "research use only" labels that everyone involved knows are destined for human biceps, bellies, and bloodstreams.
Let's meet the major players.
BPC-157 (Body Protection Compound-157)
What it is: A synthetic peptide fragment derived from a protein found in human gastric juice. It's the darling of the peptide world — promoted as a near-miraculous healing agent for tendons, ligaments, muscles, and the gut.
What the evidence says: Animal studies are numerous and genuinely interesting. In rodent models, BPC-157 has shown effects on angiogenesis, fibroblast proliferation, and tissue repair. But here's the critical point: there have been only three published human studies, including a safety pilot with exactly two participants that tested intravenous infusion of up to 20 mg in healthy adults. A Phase I trial started in 2015 was never published — the submission was reportedly cancelled. A Phase II trial for hamstring injuries has been registered but has no results.
What should give you pause: The very mechanisms being promoted as benefits — angiogenesis and fibroblast proliferation — are also well-established hallmarks of cancer progression. Tumors cannot grow beyond a few millimeters without recruiting new blood vessels; that's why an entire class of cancer drugs (anti-angiogenic therapies like bevacizumab) exists specifically to block angiogenesis. Cancer-associated fibroblasts are now recognized as major drivers of tumor invasion and metastasis. No one has studied what happens when you systemically activate these pathways with chronic BPC-157 use in humans. To be clear: there is no evidence that BPC-157 causes cancer. But there is also no evidence that it doesn't — and the biological mechanisms it promotes are the same ones that oncologists spend careers trying to suppress. A healing signal and a tumor-feeding signal are often the same signal. The difference is context — and when you inject a systemic peptide, you don't get to choose which tissues respond.
What that means: The entire body of human evidence for BPC-157 could fit on a single page. Every claim about healing tendons, curing gut issues, or reducing inflammation in humans is extrapolated from rodent studies. Rats are not small humans. The gap between "interesting in a mouse" and "safe and effective in people" is littered with the wreckage of thousands of promising molecules that didn't survive the crossing.
TB-500 (Thymosin Beta-4 Fragment)
What it is: A synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, wound healing, and inflammation.
What the evidence says: Similar to BPC-157 — animal data suggests tissue-repair properties, but human clinical trial data is essentially nonexistent. TB-500 is not FDA-approved for any human use. It is banned by WADA as a prohibited substance under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics).
The angiogenesis concern: Both BPC-157 and TB-500 promote angiogenesis — the growth of new blood vessels. In the context of healing a torn tendon, that's theoretically helpful. In the context of a pre-existing, undiagnosed tumor? Promoting blood vessel growth is exactly what a tumor needs to grow and metastasize. There are no human studies examining whether chronic use of these peptides affects cancer risk, but the mechanistic concern is biologically sound.
CJC-1295 and Ipamorelin (Growth Hormone Secretagogues)
What they are: CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a growth hormone secretagogue that stimulates the ghrelin receptor. They are often stacked together to promote growth hormone (GH) release from the pituitary gland — essentially trying to jack up your body's own GH production.
What the evidence says: These peptides have been used in research settings, but neither is FDA-approved for human use. The FDA has cited safety concerns including cardiac effects (elevated heart rate) for CJC-1295. Both were placed on the FDA's Category 2 list in late 2023, effectively barring compounding pharmacies from producing them.
The cancer question: The concern isn't that these peptides directly activate oncogenes — it's that they elevate IGF-1 (insulin-like growth factor-1), and chronically elevated IGF-1 is associated with increased cancer risk. Population studies, including data from the UK Biobank (~400,000 people), have linked higher circulating IGF-1 to colorectal, breast, and prostate cancers. Major endocrine guidelines treat active malignancy as a contraindication to growth hormone therapy. The only FDA-approved GHRH analog, tesamorelin, carries an explicit cancer warning and requires IGF-1 monitoring.
You don't need to activate an oncogene directly to promote cancer. You just need to pour fuel on a fire that might already be smoldering. Chronically elevated IGF-1 does exactly that — it promotes cell proliferation and inhibits apoptosis (programmed cell death), which is the body's quality control system for eliminating damaged or precancerous cells.
Other Notable Mentions
MK-677 (Ibutamoren): An oral growth hormone secretagogue — technically not a peptide but often grouped with them. Increases GH and IGF-1. Same cancer concerns as above, plus a two-year randomized trial found it significantly increased fasting blood glucose and worsened insulin resistance — not ideal for cardiometabolic health.
PT-141 (Bremelanotide): A melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It's the only peptide on this list with actual FDA approval for a specific use — but it's being used off-label by men in the gym community for "performance" purposes without any evidence supporting that application.
Selank and Semax: Synthetic peptides derived from natural immunomodulatory peptides. Promoted as nootropics (cognitive enhancers) and anxiolytics. Developed in Russia, approved there for certain uses, but no FDA approval and minimal Western clinical data — the majority of evidence comes from small, Russian-language studies with limited independent replication.
Part III: The Regulatory Wasteland
The regulatory landscape for peptides is, to put it charitably, a mess.
These substances exist in a gray zone that the FDA has struggled to police. They're not approved drugs. They're not dietary supplements (though some sellers try to market them as such). They're sold with "for research use only" labels — a legal fig leaf that fools no one. As one legal analysis noted, the FDA has rejected "research use only" disclaimers in warning letters when the website clearly showed intended human use.
In late 2023, the FDA moved approximately 19 peptides — including TB-500, CJC-1295, and ipamorelin — to Category 2 of its bulks list, effectively barring compounding pharmacies from producing them. But the enforcement has been uneven. A July 2026 FDA advisory panel recommended broadening access to four popular peptides — though these are only recommendations, and a legal analysis from Hogan Lovells estimates a clear federal pathway is unlikely before 2027 and may not be finalized until 2028.
Meanwhile, the gray market thrives. Forbes reported that cross-border supply chains from China make enforcement difficult, and blockchain analytics firm Chainalysis estimated $32 million in gray-market peptide cryptocurrency transactions in Q1 2026 alone. Independent testing has found endotoxin contamination in approximately 8% of samples, and some vials contained none of the labeled compound.
Let that sink in. You could be injecting yourself with nothing. Or worse — you could be injecting yourself with bacterial endotoxins, heavy metals, or unknown impurities from a factory in China that has never been inspected by any regulatory authority.
Part IV: The CardioAdvocate Bottom Line
GLP-1 receptor agonists are genuinely remarkable drugs — for the people they were designed and tested for. In patients with obesity, type 2 diabetes, and cardiovascular disease, semaglutide and tirzepatide have delivered meaningful improvements in weight, glycemic control, cardiovascular outcomes, and quality of life. The SELECT trial showed a 20% reduction in major adverse cardiovascular events. These are practice-changing medications.
But a drug that helps a sick population is not automatically safe for a healthy one. The clinical trials did not enroll gym-goers with normal BMIs. The risk-benefit calculus changes entirely when there is no disease to treat. The potential for muscle loss, gallbladder disease, reward-circuit disruption, and unknown long-term effects in lean, healthy individuals is real and unstudied.
Compounded semaglutide is not Ozempic. Salt forms are not the same active ingredient. There are no clinical trials, no standardized manufacturing, and a disturbing track record of contamination and adverse events. The shortage is over. The legal basis is gone. What remains is an unregulated market selling you an untested product at a discount.
Research peptides are exactly what the label says: research. BPC-157 has three human studies, including a two-person pilot. CJC-1295 and ipamorelin have no FDA approval and carry known safety signals. TB-500 is banned by WADA. The evidence base for injecting these substances into your body consists almost entirely of rodent studies and internet testimonials. Chronically elevating IGF-1 carries a credible cancer risk. Promoting angiogenesis in someone with an undiagnosed tumor could accelerate its growth.
The gym is not a pharmacy. Your trainer is not your doctor. The person selling you peptides at the counter did not go to medical school. They did not review the literature. They do not know your family history, your thyroid function, your IGF-1 levels, or whether you have a subclinical malignancy. They know that their last client "felt amazing" and lost 8 pounds.
We are not anti-peptide at CardioAdvocate. We are pro-evidence. Some of these compounds may eventually prove useful. Some may even be revolutionary. But "may" is not "does," and the gap between promising preclinical data and proven human benefit is where careers in drug development go to die. You should not be the one bridging that gap with your own body — especially when the vial you're injecting may not even contain what the label says.
Questions to Ask Before Injecting Anything
☑ Is this substance FDA-approved for any human use?
☑ Has it been tested in randomized controlled trials in humans?
☑ Were those trials conducted in people like me — healthy, lean, non-diabetic?
☑ Is the source a licensed pharmacy or an unregulated online seller?
☑ Has this specific product been tested for purity, potency, and sterility?
☑ What are the known side effects — and what are the unknown risks?
☑ Does my doctor know I'm taking this?
☑ If something goes wrong, is there a clinical pathway for treatment?
☑ Am I making this decision based on evidence — or based on what someone at the gym said worked for them?
Advocating for your heart. Questioning the hype.
CardioAdvocate — Evidence over anecdote. Always.
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The information presented reflects published evidence as of October 2026. Always consult a qualified healthcare provider before starting any medication, supplement, or peptide therapy. CardioAdvocate has no financial relationships with any pharmaceutical or peptide manufacturer.
